Quick generation of fully mature dendritic cells from monocytes with OK432, low-dose prostanoid, and interferon-α as potent immune enhancers

Journal of Immunotherapy

Volumn 29, Issue 1, 2006, Pages 67-77

  Sakakibara, Mitsuru ^a   Kanto, Tatsuya ^a   Inoue, Michiyo ^a   Kaimori, Aki ^a   Yakushijin, Takayuki ^a   Miyatake, Hideki ^a   Itose, Ichiyo ^a   Miyazaki, Masanori ^a   Kuzushita, Noriyoshi ^a   Hiramatsu, Naoki ^a   Takehara, Tetsuo ^a   Kasahara, Akinori ^a   Hayashi, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer immune therapy; Dendritic cells; Interferon ; OK432; Prostaglandin E2

Indexed keywords

ALPHA INTERFERON; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 27; MESSENGER RNA; PICIBANIL; PROSTAGLANDIN E2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; RECOMBINANT INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 7; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; IMMUNOLOGICAL ADJUVANT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CELL MIGRATION; CLINICAL ARTICLE; COLON CANCER; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MONOCYTE; NATURAL KILLER T CELL; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; STREPTOCOCCUS PYOGENES; CELL MOTION; COLON TUMOR; CULTURE TECHNIQUE; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METHODOLOGY; MIDDLE AGED; STOMACH TUMOR;

ADJUVANTS, IMMUNOLOGIC; AGED; CELL CULTURE TECHNIQUES; CELL MOVEMENT; COLONIC NEOPLASMS; DENDRITIC CELLS; DINOPROSTONE; HUMANS; INTERFERON-ALPHA; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MONOCYTES; PICIBANIL; STOMACH NEOPLASMS;

EID: 33644826675     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000183093.77687.46     Document Type: Article

References (29)

1. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest. 2003;21:873-886.
2. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135-3142.
3. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9:5091-5100.
4. Vilella R, Benitez D, Mila J, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother. 2004;53:651-658.
5. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002;195:1279-1288.
6. Lee AW, Truong T, Bickham K, et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine. 2002;20(Suppl 4):A8-A22.
7. Alli RS, Khar A. Interleukin-12 secreted by mature dendritic cells mediates activation of NK cell function. FEBS Lett. 2004;559:71-76.
8. Mbawuike IN, Fujihashi K, DiFabio S, et al. Human interleukin-12 enhances interferon-gamma-producing influenza-specific memory CD8+ cytotoxic T lymphocytes. J Infect Dis. 1999;180:1477-1486.
9. Dredge K, Marriott JB, Todryk SM, et al. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother. 2002;51:521-531.
10. Toes RE, Offringa R, Feltkamp MC, et al. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes. Behring Inst Mitt. 1994;94:72-86.
11. Okada N, Mori N, Koretomo R, et al. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther. 2005;12:129-139.
12. Hirao M, Onai N, Hiroishi K, et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res. 2000;60:2209-2217.
13. Kim KD, Choi SC, Kim A, et al. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction. Int Immunopharmacol. 2001;1:2117-2129.
14. Nishimura T, Nakui M, Sato M, et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol. 2000;46 (Suppl):S52-S61.
15. Dauer M, Obermaier B, Herten J, et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol. 2003;170:4069-4076.
16. Nakahara S, Tsunoda T, Baba T, et al. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 2003;63:4112-4118.
17. Itoh T, Ueda Y, Okugawa K, et al. Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol Immunother. 2003;52:207-214.
18. Nukaya I, Yasumoto M, Iwasaki T, et al. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer. 1999;80:92-97.
19. Ito A, Kanto T, Kuzushita N, et al. Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells. J Gastroenterol Hepatol. 2001;16:309-316.
20. Scandella E, Men Y, Gillessen S, et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood. 2002;100:1354-1361.
21. Kalinski P, Vieira PL, Schuitemaker JH, et al. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001;97:3466-3469.
22. Brombacher F, Kastelein RA,Alber G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 2003;24:207-212.
23. Figdor CG, De Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004;10:475-480.
24. Curti A, Isidori A, Ferri E, et al. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. Leuk Lymphoma. 2004;45:1419-1428.
25. Sorg RV, Ozean Z, Brefort T, et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother. 2003;26:374-383.
26. Wong EC, Maher VE, Hines K, et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy. 2001;3:19-29.
27. Moldenhauer A, Nociari MM, Dias S, et al. Optimized culture conditions for the generation of dendritic cells from peripheral blood monocytes. Vox Sang. 2003;84:228-236.
28. Kubo S, Takahashi HK, Takei M, et al. EP (E-Prostanoid)2/EP4-receptor- dependent maturation of human monocyte-derived dendritic cells and induction of Th2 polarization. J Pharmacol Exp Ther. 2004;9:9-99.
29. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4:941-952.